MedTrace Logo

Randomized Study of Albuterol in Patients With Facioscapulohumeral Muscular Dystrophy

NCT00004685 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2015-03-25

No results posted yet for this study

Summary

OBJECTIVES: I. Determine whether albuterol increases strength in patients with facioscapulohumeral dystrophy as measured by quantitative voluntary isometric contraction testing.

II. Determine whether albuterol increases muscle mass in this patient population as determined by 24 hour urinary creatinine excretion and dual energy x-ray absorptiometry (DEXA).

III. Examine the long term safety of albuterol in this patient population.

Conditions

  • Muscular Dystrophy, Facioscapulohumeral

Interventions

DRUG

albuterol

Sponsors & Collaborators

  • Ohio State University

    lead OTHER

Principal Investigators

  • John T. Kissel · Ohio State University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1998-01-31
Completion
2000-09-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00004685 on ClinicalTrials.gov